US senator alleges FDA tried to prevent Adderall XR withdrawal in Canada

Eggertson, Laura
March 2005
CMAJ: Canadian Medical Association Journal;3/29/2005, Vol. 172 Issue 7, p865
Academic Journal
Reports on the allegations of U.S. senators that the Food and Drug Administration (FDA) tried to prevent the withdrawal of amphetamine salts Adderall XR in the Canadian market. Therapeutic applications of Adderall; Highlights of hearings investigating the FDA; Possible adverse effects of the drug.


Related Articles

  • Washington letter.  // DCI;Oct94, Vol. 155 Issue 4, p8 

    Reports on the US Senate's agreement to a House request deleting user fees previously instituted by the Senate on its funding bill of the US Food & Drug Administration (FDA). House authority to originate revenue measures; Decision to come up with alternative funding.

  • FDA budget seems destined for cuts.  // Ophthalmology Times;7/10/95, Vol. 20 Issue 26, p3 

    Reports on the downsizing of US Food and Drug Administration's budget for 1996 by the House of Appropriations Committee. Limit of funds for overhead, publications and congressional affairs; Reallocations.

  • FDA budget cuts expected to delay drug approval rate.  // Chemical Market Reporter;04/07/97, Vol. 251 Issue 14, p14 

    Discloses the effect of a proposal by President Bill Clinton to cut back the budget of the United States Food and Drug Administration (FDA). Delay in drug approval rate; Total allocations for the FDA until 1997; Estimated fiscal 1998 funding for the agency; Improvements to the prescription drug...

  • Livable FDA budget advances. Dickinson, James G. // Medical Marketing & Media;Aug97, Vol. 32 Issue 8, p35 

    Reports on the US House Appropriations Committee's approval of the Food and Drug Administration's (FDA) fiscal year 1998 budget. Level funding for human drugs; FDA's total appropriation.

  • FDA spending plan mired at Office of Management & Budget.  // Medical Marketing & Media;Feb98, Vol. 33 Issue 2, p28 

    Reports that the US Food and Drug Administration (FDA) missed its new statutory December 22, 1997 deadline for filing an operating plan for fiscal year 1998 with the US Congress. Delay in the White House's Office of Management and Budget.

  • Washington letter.  // DCI;Aug94, Vol. 155 Issue 2, p8 

    Reports on the US Senate Appropriations Committee's decision to include user fees in the 1995 Food & Drug Administration (FDA) budget. Probability of House of Representatives' voting against the idea; Opposition to user fees by Cosmetic, Toiletry & Fragrance Association.

  • FDA budget gets a boost.  // Medical Marketing & Media;Apr2003, Vol. 38 Issue 4, p16 

    Reports on the increase in the budget of the U.S. Food and Drug Administration (FDA). Increase in drug user fees; Authorization of funds to be collected from medical device user fees; Approval of the appropriation bill in February 2003; Funds provided for the agency's counter-terrorism initiatives.

  • Bush Budget Combats Bioterrorism. Wechsler, Jill // Pharmaceutical Technology Europe;Apr2002, Vol. 14 Issue 4, p20 

    Reports on the federal budget proposal for 2003 fiscal year which aimed to give the U.S. Food and Drug Administration (FDA) more resources to boost plant inspections and improve drug safety. Effect of the budget plan on the manufacturer user fees; Reason for the goal of FDA to increase user fee...

  • Waxman to NAPM: FDA user fees will speed up generic approvals.  // Drug Store News;8/4/97, Vol. 19 Issue 12, p19 

    Focuses on the US Food & Drug Administration (FDA) funding issues concerning generic drugs approval in the United States. Potential impact of a budget shortfall on generics approval in 1998; Suggestion that industry leaders consider dropping their opposition to the imposition of user fees to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics